Cognos Announces U.S. Patent Award for Cerebral Microdialysis
We hope that our patent will eventually enable safer and more effective treatment of neurological diseases, such as Alzheimer’s,” said Frank Adell, Chief Executive Officer of Cognos.
- We hope that our patent will eventually enable safer and more effective treatment of neurological diseases, such as Alzheimer’s,” said Frank Adell, Chief Executive Officer of Cognos.
- Cognos intends to develop the patented technology to enable cerebrospinal fluid (“CSF”) dialysis, where CSF is filtered from protein debris.
- We are excited about the potential impact our technology could have on Alzheimer’s patients and their families,” concluded Mr. Adell.
- Cognos has an extensive portfolio of patents and patent applications covering all key products, with over 30 exclusively owned patents that cover jurisdictions in the U.S., Canada, Mexico, China, Europe, Australia, and Japan.